NO20052310L - Posisjonsisomerer av PEG IFN alfa 2A. - Google Patents

Posisjonsisomerer av PEG IFN alfa 2A.

Info

Publication number
NO20052310L
NO20052310L NO20052310A NO20052310A NO20052310L NO 20052310 L NO20052310 L NO 20052310L NO 20052310 A NO20052310 A NO 20052310A NO 20052310 A NO20052310 A NO 20052310A NO 20052310 L NO20052310 L NO 20052310L
Authority
NO
Norway
Prior art keywords
position isomers
peg ifn
ifn alfa
alfa
treatment
Prior art date
Application number
NO20052310A
Other languages
English (en)
Other versions
NO20052310D0 (no
Inventor
Doris Brugger
Stefan Foser
Alfred Schacher
Karl Weyer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20052310D0 publication Critical patent/NO20052310D0/no
Publication of NO20052310L publication Critical patent/NO20052310L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Oppfinnelsen angår posisjonsisomerer av monopegylert interferon-alfa 2a, fremgangsmåte for deres isolering og anvendelse av dem for fremstilling av medikamenter for behandling av sykdommer, spesielt for behandling av virale sykdommer.
NO20052310A 2002-11-15 2005-05-11 Posisjonsisomerer av PEG IFN alfa 2A. NO20052310L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02025585 2002-11-15
PCT/EP2003/012498 WO2004045648A1 (en) 2002-11-15 2003-11-10 Positional isomers of peg ifn alpha 2a

Publications (2)

Publication Number Publication Date
NO20052310D0 NO20052310D0 (no) 2005-05-11
NO20052310L true NO20052310L (no) 2005-08-09

Family

ID=32319537

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052310A NO20052310L (no) 2002-11-15 2005-05-11 Posisjonsisomerer av PEG IFN alfa 2A.

Country Status (23)

Country Link
US (1) US20040223950A1 (no)
EP (1) EP1562634B1 (no)
JP (1) JP4279258B2 (no)
KR (1) KR20050065677A (no)
CN (1) CN1323722C (no)
AR (1) AR042039A1 (no)
AT (1) ATE337017T1 (no)
AU (1) AU2003293668A1 (no)
BR (1) BR0316227A (no)
CA (1) CA2503594C (no)
DE (1) DE60307881T2 (no)
ES (1) ES2270152T3 (no)
GT (1) GT200300244A (no)
MX (1) MXPA05005178A (no)
NO (1) NO20052310L (no)
PA (1) PA8587801A1 (no)
PE (1) PE20040834A1 (no)
PL (1) PL376883A1 (no)
RU (1) RU2005118752A (no)
TW (1) TW200413404A (no)
UY (1) UY28080A1 (no)
WO (1) WO2004045648A1 (no)
ZA (1) ZA200503756B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CA2504267A1 (en) * 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
MXPA06013412A (es) 2004-05-19 2007-01-23 Maxygen Inc Polipeptidos de interferon-alfa y conjugados.
JP2008545393A (ja) 2005-05-18 2008-12-18 マキシジェン， インコーポレイテッド 進歩したインターフェロンαポリペプチド
US7695710B2 (en) 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
EP1901777A2 (en) * 2005-06-20 2008-03-26 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon-alpha analogs and interferon tau
CN101002944B (zh) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
ES2382124T3 (es) * 2007-09-04 2012-06-05 Biosteed Gene Expression Tech. Co., Ltd. Interferón alfa 2b modificado con polietilenglicol y método de preparación y aplicaciones de este
DK2196475T3 (da) * 2007-09-04 2012-09-17 Biosteed Gene Expression Tech Co Ltd Interferon alfa 2a, som er modificeret med polyethylenglycol, fremgangsmåde til syntese deraf samt anvendelse deraf
MX2010010953A (es) 2008-04-03 2011-04-21 Biosteed Gene Expression Tech Co Ltd Hormona de crecimiento modificada con glicol de polietileno de doble cadena, metodo de preparacion y aplicación del a misma.
US9272048B2 (en) 2008-04-29 2016-03-01 Ascendis Pharma Growth Disorders Division A/S PEGylated recombinant human growth hormone compounds
EP2113256A1 (en) 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
DE102009009344B4 (de) * 2009-02-05 2018-01-04 Helmholtz-Zentrum Dresden - Rossendorf E.V. Verfahren und Anordnung zur Reinigung des Reaktionsgemisches bei der Herstellung von Radiopharmaka
WO2010110503A1 (ko) * 2009-03-27 2010-09-30 주식회사 중외제약 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질
CN101514229B (zh) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物
CN106749608B (zh) * 2015-11-18 2021-10-15 石药集团中奇制药技术（石家庄）有限公司 干扰素α缀合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
JP2006508918A (ja) * 2002-09-05 2006-03-16 ザ ジェネラル ホスピタル コーポレーション 修飾されたアシアロインターフェロンおよびその使用

Also Published As

Publication number Publication date
DE60307881T2 (de) 2007-03-08
US20040223950A1 (en) 2004-11-11
PA8587801A1 (es) 2004-09-16
CA2503594A1 (en) 2004-06-03
ATE337017T1 (de) 2006-09-15
NO20052310D0 (no) 2005-05-11
CN1323722C (zh) 2007-07-04
EP1562634A1 (en) 2005-08-17
JP4279258B2 (ja) 2009-06-17
UY28080A1 (es) 2004-05-31
CN1711109A (zh) 2005-12-21
AR042039A1 (es) 2005-06-08
BR0316227A (pt) 2005-10-04
PL376883A1 (pl) 2006-01-09
MXPA05005178A (es) 2005-07-22
TW200413404A (en) 2004-08-01
DE60307881D1 (de) 2006-10-05
ES2270152T3 (es) 2007-04-01
CA2503594C (en) 2011-05-10
GT200300244A (es) 2004-06-03
AU2003293668A1 (en) 2004-06-15
WO2004045648A1 (en) 2004-06-03
EP1562634B1 (en) 2006-08-23
KR20050065677A (ko) 2005-06-29
ZA200503756B (en) 2008-02-27
JP2006515571A (ja) 2006-06-01
PE20040834A1 (es) 2004-11-17
RU2005118752A (ru) 2006-02-10

Similar Documents

Publication Publication Date Title
NO20052310L (no) Posisjonsisomerer av PEG IFN alfa 2A.
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
TW200510343A (en) Substituted dihydroquinazolines
DOP2002000429A (es) Imidazotriazinas
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
BR122020006906B8 (pt) compostos e composições farmacêuticas antivirais
ATE453642T1 (de) Substituierte phenylaminopyrimidine
WO2004014312A3 (en) Small-mer compositions and methods of use
TW200633718A (en) Treatment of hepatitis c in the asian population
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
BRPI0416936A (pt) sistemas de anel de imidazo substituìdos e métodos
WO2004071426A3 (en) Compounds for the treatment of viral infection
DE60215157D1 (de) Verwendungen von antiviralen nucleosid-derivaten zur herstellung eines medikaments zur behandlung von hepatitis c infektionen
NO20033123D0 (no) Terapeutisk hinnedannende sammensetning og behandlingsplan derav
UY28313A1 (es) Nonadepsipeptidos acilados
TW200621799A (en) Acylated nonadepsipeptides II
ATE433459T1 (de) Desoxo-nonadepsipeptide
HK1097467A1 (en) Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids
ATE455789T1 (de) Substituierte nonadepsipeptide
DK1476467T3 (da) IgG3-immunglobulin som beskyttelsesmarkör mod virusinfektionssygdomme og anvendelser deraf
ECSP034872A (es) Nuevos heterociclos 3
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
DE60231605D1 (de) Immunomodulator zur bekämpfung von durch humanen immunschwächevirus (hiv) vermittelte krankheiten/infektionen